Is FDA Approval for Aging Going to Be an Important Piece of the Puzzle?

Rapamycin doesn't have to be approved by FDA for anything more at this point because it's already approved. So I think there's a lot of misunderstanding around what FDA is looking for when we're talking about drugs that target the biology of aging. We need quantitative endpoints that either are surrogates for biological aging, and that's where these clocks may come in. There's really nothing saying you couldn't do a clinical trial showing that you can improve muscle function in the elderly and not get a drug approved for that.

Transcript

Play full episode

Transcript

Episode notes

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app